• Email:sales@AmericanPharmaWholesale.com
  • Site Map




Please email us at Sales@AmericanPharmaWholesale.com with our item No, NDC#, UPC# or best is product link. We are located in Oceanside, California. Search over 100,000 items by Name, Item No., NDC, UPC (without dashes) or by Mfg.Name.


Menu

Cosyntropin N+ 0.25mg Vial 10 by Mylan Institutional

NDC 67457-0257-02 UPC/GTIN No.3-67457-25702-0 Mfg.Part No.25702Mylan Institutional/GenThis Item Can Only Be Ordered By A Drug Mfg, Wholesaler,Pharmacy,Physician, Dentist, Podiatrist, Optometrist,Veterinarian,Naturopath,Licensed Lab, Physical Therapist & Pharmacist(scope).Mylan Institutional/GenImage 4 of Cosyntropin N+ 0.25mg Vial 10 by Mylan Institutional

Cosyntropin N+ 0.25mg Vial 10 by Mylan Institutional

$962.40$699.00

NDC No. 67457-0257-02 UPC/GTIN No. 3-67457-25702-0 MPN 25702 Only Physician,Pharmacy or Licensed Facility can order this Rx Item No. Rx197970 Cosyntrop N+ 0.25mg Vial 10 by Mylan Institutional Item No. 3197970 NDC No. 67457025702 UPC No. 367457257020 Other Name Cosyntropin,Cortrosyn Therapeutic Code 360400 Therapeutic Class Adrenocortical Insufficiency Item Class Non Controlled Rx. Case Qnty: 16 Therapeutic Code 360400 Adrenocortical Insufficiency Info Adrenocorticotropic Hormone [Chemical/Ingr

Have a question?

  Please click: Have a question? or email us at sales@AmericanPharmaWholesale.com for current price and availability.

COSYNTROPIN- cosyntropin injection, powder, lyophilized, for solution
Sandoz Inc

DESCRIPTION

Cosyntropin for Injection is a sterile lyophilized powder in vials containing 0.25 mg of Cosyntropin and 10 mg of mannitol to be reconstituted with 1 mL of 0.9% Sodium Chloride Injection, USP. Administration is by intravenous or intramuscular injection. Cosyntropin is a 1 to 24 corticotropin, a synthetic subunit of ACTH. It is an open chain polypeptide containing, from the N terminus, the first 24 of the 39 amino acids of natural ACTH. The sequence of amino acids in the 1 to 24 compounds is as follows:

Image 1
(click image for full-size original)
CLINICAL PHARMACOLOGY



Cosyntropin for Injection exhibits the full corticosteroidogenic activity of natural ACTH. Various studies have shown that the biologic activity of ACTH resides in the N-terminal portion of the molecule and that the 1 to 20 amino acid residue is the minimal sequence retaining full activity. Partial or complete loss of activity is noted with progressive shortening of the chain beyond 20 amino acid residues. For example, the decrement from 20 to 19 results in a 70% loss of potency.

The pharmacologic profile of Cosyntropin for Injection is similar to that of purified natural ACTH. It has been established that 0.25 mg of will stimulate the adrenal cortex maximally and to the same extent as 25 units of natural ACTH. This dose of Cosyntropin for Injection will produce maximal secretion of 17-OH corticosteroids, 17- ketosteroids and / or 17 - ketogenic steroids.

The extra-adrenal effects which natural ACTH and Cosyntropin for Injection have in common include increased melanotropic activity, increased growth hormone secretion and an adipokinetic effect. These are considered to be without physiological or clinical significance.

Animal, human and synthetic ACTH (1 to 39) which all contain 39 amino acids exhibit similar immunologic activity. This activity resides in the C-terminal portion of the molecule and the 22 to 39 amino acid residues exhibit the greatest degree of antigenicity. In contrast, synthetic polypeptides containing 1 to 19 or fewer amino acids have no detectable immunologic activity. Those containing 1 to 26, 1 to 24 or 1 to 23 amino acids have very little immunologic although full biologic activity. This property of Cosyntropin for Injection assumes added importance in view of the known antigenicity of natural ACTH.

INDICATIONS AND USAGE

Cosyntropin for Injection is intended for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. Because of its rapid effect on the adrenal cortex it may be utilized to perform a 30-minute test of adrenal function (plasma cortisol response) as an office or outpatient procedure, using only 2 venipunctures (see DOSAGE AND ADMINISTRATION section).

Severe hypofunction of the pituitary - adrenal axis is usually associated with subnormal plasma cortisol values but a low basal level is not per se evidence of adrenal insufficiency and does not suffice to make the diagnosis. Many patients with proven insufficiency will have normal basal levels and will develop signs of insufficiency only when stressed. For this reason a criterion which should be used in establishing the diagnosis is the failure to respond to adequate corticotropin stimulation. When presumptive adrenal insufficiency is diagnosed by a subnormal Cosyntropin for Injection test, further studies are indicated to determine if it is primary or secondary.

Primary adrenal insufficiency (Addison's disease) is the result of an intrinsic disease process, such as tuberculosis within the gland. The production of adrenocortical hormones is deficient despite high ACTH levels (feedback mechanism). Secondary or relative insufficiency arises as the result of defective production of ACTH leading in turn to disuse atrophy of the adrenal cortex. It is commonly seen, for example, as result of corticosteroid therapy, Sheehan's syndrome and pituitary tumors or ablation.

The differentiation of both types is based on the premise that a primarily defective gland cannot be stimulated by ACTH whereas a secondarily defective gland is potentially functional and will respond to adequate stimulation with ACTH. Patients selected for further study as the result of a subnormal Cosyntropin for Injection test should be given a 3 or 4 day course of treatment with Repository Corticotropin Injection USP and then retested. Suggested doses are 40 USP units twice daily for 4 days or 60 USP units twice daily for 3 days. Under these conditions little or no increase in plasma cortisol levels will be seen in Addison's disease whereas higher or even normal levels will be seen in cases with secondary adrenal insufficiency.

NDC 67457-0257-02 UPC/GTIN No.3-67457-25702-0 Mfg.Part No.25702
Cosyntrop N+ 0.25mg Vial 10 by Mylan Ins
NDC 67457-0257-02 UPC/GTIN No.3-67457-25702-0 Mfg.Part No.25702

Mylan Institutional/Gen

Mylan Institutional/Gen

This Item Can Only Be Ordered By A Drug Mfg, Wholesaler,Pharmacy,Physician, Dentist, Podiatrist, Optometrist,Veterinarian,Naturopath,Licensed Lab, Physical Therapist & Pharmacist(scope).
COSYNTROPIN INJECTION VIA
This Item Can Only Be Ordered By A Drug Mfg, Wholesaler,Pharmacy,Physician, Dentist, Podiatrist, Optometrist,Veterinarian,Naturopath,Licensed Lab, Physical Therapist & Pharmacist(scope).